Protenus Granted Seventh Patent for Drug Diversion Surveillance Technology
New patent granted assists hospitals with greater coverage to support drug waste events
BALTIMORE, July 18, 2024 (Newswire.com) - Protenus, provider of the leading healthcare compliance analytics platform, today announced a new grant of a U.S. Patent that supports its ongoing efforts to deliver drug diversion surveillance technology that enables hospitals and health systems to be more efficient and proactively eliminate risk to their organization and patients.
The new grant of U.S. Patent No. 12,033,736 is titled “Methods and Systems for Analyzing Accessing of Drug Dispensing Systems.” With this patent, Protenus now holds seven granted U.S. patents covering various techniques for detecting anomalous drug dispensing events. The newly granted patent covers the usage of rules or patterns for determining when a drug wasting event is a misappropriation event. The patent further describes modifying the rules or patterns for detecting possible subsequent misappropriation events.
“Policies and prevention tactics alone will not eliminate the diversion or misappropriation of controlled substance waste. Waste disposal should be audited, especially in high-use and complex care settings,” states Nick Culbertson, CEO and Co-Founder of Protenus. He continues, “Our award-winning drug diversion surveillance solution is designed to review drug handling patterns by monitoring 100% of medication handling transactions, bringing suspicious or likely events to the attention of the health system’s investigator for further review. This new patent reflects our continued commitment to supporting the complex intricacies of our customers’ diversion monitoring strategies.”
Protenus holds more than a dozen granted U.S. patents covering various key aspects of patient privacy monitoring and drug diversion surveillance technologies, along with several other pending U.S. and foreign patent applications.
Any licensing inquiries or other questions about the Protenus patent portfolio should be directed to Amy Much, Protenus's General Counsel, at amy.much@protenus.com.
Source: Protenus
